These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19418305)

  • 1. Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer.
    Rentsch CA; Cecchini MG; Thalmann GN
    Swiss Med Wkly; 2009 Apr; 139(15-16):220-5. PubMed ID: 19418305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review.
    Chappard D; Bouvard B; Baslé MF; Legrand E; Audran M
    Morphologie; 2011 Jun; 95(309):65-75. PubMed ID: 21620753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Wnts in prostate cancer bone metastases.
    Hall CL; Kang S; MacDougald OA; Keller ET
    J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Osteosclerosis related with bone morphogenetic protein (BMP)].
    Ando W; Hashimoto J; Yoshikawa H
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():444-9. PubMed ID: 16279680
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pathophysiology of bone metastases].
    Chappard D; Legrand E; Massin P; Basle MF; Audran M
    Prog Urol; 2003 Apr; 13(2 Suppl 1):9-17. PubMed ID: 12815804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.
    Secondini C; Wetterwald A; Schwaninger R; Thalmann GN; Cecchini MG
    PLoS One; 2011 Jan; 6(1):e16078. PubMed ID: 21249149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential.
    Ye L; Mason MD; Jiang WG
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):865-97. PubMed ID: 21196208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis.
    Zheng Y; Zhou H; Fong-Yee C; Modzelewski JR; Seibel MJ; Dunstan CR
    Clin Exp Metastasis; 2008; 25(5):559-67. PubMed ID: 18421566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
    Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.
    Spanjol J; Djordjević G; Markić D; Klarić M; Fuckar D; Bobinac D
    Coll Antropol; 2010 Apr; 34 Suppl 2():119-25. PubMed ID: 21302710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathophysiology of bone metastases and new molecular targets involved in bone remodelling].
    Clézardin P
    Bull Cancer; 2013 Nov; 100(11):1083-91. PubMed ID: 24152978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
    Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
    Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When prostate cancer meets bone: control by wnts.
    Emami KH; Corey E
    Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
    Autzen P; Robson CN; Bjartell A; Malcolm AJ; Johnson MI; Neal DE; Hamdy FC
    Br J Cancer; 1998 Nov; 78(9):1219-23. PubMed ID: 9820184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
    Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
    Reddi AH; Roodman D; Freeman C; Mohla S
    J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of osteoblastic bone metastases from prostate cancer.
    Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
    Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.